Mohammad Ali Mirshekar

Dr. Mohammad Ali Mirshekar


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
ASAli Shamsi-Goushki
Ali Shamsi-Goushki
ZMZinat Mortazavi
Zinat Mortazavi
MMMohammad Ali Mirshekar
Mohammad Ali Mirshekar
MMMahdi Mohammadi
Mahdi Mohammadi
Nasrollah MoradikorNasrollah Moradikor
Nasrollah Moradikor
MSMansour Shahraki
Mansour Shahraki
Background and Purpose: Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and abnormalities in insulin production. Apelin is associated with insulin resistance. According to the anti-diabetic properties of curcumin, the purpose of this study was to compare the effects of curcumin and nano-curcumin intake on insulin resistance and serum levels of fasting blood sugar (FBS), Apelin, and lipid profile (cholesterol, triglyceride, LDL, HDL and VLDL) in T2DM rats. Materials and Methods: Forty-eight male Wistar rats were divided into six groups: Control, diabetic, diabetic treated with two doses of curcumin (100 and 200 mg/kg) and diabetic treated with two doses of nano-curcumin (100 and 200 mg/kg). Induction of T2DM was performed by intraperitoneal injection of Nicotinamide (110 mg/kg) and Streptozotocin (45 mg/kg) in the fasting state. Rats received different doses of nano-curcumin and curcumin by gavage (daily) for 28 days. At the end of the intervention period, insulin resistance and serum levels of FBS, apelin and lipid profiles were measured. Results: Insulin resistance and serum levels of FBS, Apelin, cholesterol, triglycerides, LDL, and VLDL were significantly decreased in diabetic rats treated with curcumin and nano-curcumin (p< 0.05) so that nano-curcumin in reducing lipid profile is more effective than curcumin (P< 0.05). Serum level of HDL in nano-curcumin groups was significantly higher than diabetic and curcumin groups (p< 0.05). Also, with increasing insulin resistance, serum level of apelin increased (P< 0.05). Conclusion: The therapeutic effects of curcumin and nano-curcumin were effective in decreasing insulin resistance, serum levels of FBS, apelin and lipid profile. The dose of 100 mg/kg nano-curcumin was more effective in reducing lipid profile.

1 August 2015 in Canadian Journal of Physiology and Pharmacology
Verified
Journal Article
Closed access
ASAlireza Sarkaki
Alireza Sarkaki
YFYaghoob Farbood
Yaghoob Farbood
MGMohammad Kazem Gharib-Naseri
Mohammad Kazem Gharib-Naseri
MBMohammad Badavi
Mohammad Badavi
MMMohammad Taghi Mansouri
Mohammad Taghi Mansouri
MMMohammad Ali Mirshekar
Mohammad Ali Mirshekar
Traumatic brain injury (TBI) is one of the main causes of intellectual and cognitive disabilities. In the clinic it is essential to limit the development of cognitive impairment after TBI. In this study, the effects of gallic acid (GA; 100 mg/kg, per oral, from 7 days before to 2 days after TBI induction) on neurological score, passive avoidance memory, long-term potentiation (LTP) deficits, and levels of proinflammatory cytokines including interleukin-1 beta (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor-α (TNF-α) in the brain have been evaluated. Brain injury was induced following Marmarou’s method. Data were analyzed by one-way and repeated measures ANOVA followed by Tukey’s post-hoc test. The results indicated that memory was significantly impaired (p < 0.001) in the group treated with TBI + vehicle, together with deterioration of the hippocampal LTP and increased brain tissue levels of IL-1β, IL-6, and TNF-α. GA treatment significantly improved memory and LTP in the TBI rats. The brain tissue levels of IL-1β, IL-6, and TNF-α were significantly reduced (p < 0.001) in the group treated with GA. The results suggest that GA has neuroprotective properties against TBI-induced behavioral, electrophysiological, and inflammatory disorders, probably via the decrease of cerebral proinflammatory cytokines.

1 February 2016 in Pharmaceutical Biology
Verified
Journal Article
Closed access
PDF file
MMMohammad Taghi Mansouri
Mohammad Taghi Mansouri
YFYaghoob Farbood
Yaghoob Farbood
BNBahareh Naghizadeh
Bahareh Naghizadeh
SSSohreh Shabani
Sohreh Shabani
MMMohammad Ali Mirshekar
Mohammad Ali Mirshekar
ASAlireza Sarkaki
Alireza Sarkaki
Context In a previous study, it has been shown that ellagic acid (EA), a polyphenolic compound found in pomegranate and different berries, prevents cognitive and hippocampal long-term potentiation (LTP) impairments induced by traumatic brain injury in rats through antioxidant and anti-inflammatory mechanisms. Objective The present study was conducted to assess the potential of EA as a memory enhancer. Materials and methods The elevated plus maze (EPM) and passive avoidance (PA) paradigm were used to evaluate learning and memory parameters. Three doses (10, 30 and 100 mg/kg, i.p.) of EA were administered to animals. Memory impairment was induced by scopolamine treatment (0.4 mg/kg, i.p.) and/or diazepam (1 mg/kg, i.p.). Acquisition trials were carried out 30 min after scopolamine treatment and retention trials were performed for 5 min 24 h after the acquisition trials. Results EA at doses 30 and 100 mg/kg significantly reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) in the EPM and PA tests in mice. Also, EA at doses 30 and 100 mg/kg significantly antagonized the amnesia induced by diazepam (1 mg/kg, i.p.) in EPM test in rats. Moreover, chronic administration of EA at dose 30 mg/kg ameliorated the memory deficit induced by diazepam (1 mg/kg, i.p.) in rats. Discussion and conclusion This study demonstrates that ellagic acid is effective in preventing scopolamine- and diazepam-induced cognitive impairments without altering the animals’ locomotion. This suggests the potential of EA application as a useful memory restorative agent in the treatment of dementia seen in elderly persons.

1 September 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
MMMohammad Ali Mirshekar
Mohammad Ali Mirshekar
HFHamed Fanaei
Hamed Fanaei
FKFereshteh Keikhaei
Fereshteh Keikhaei
FJFatemeh Sargolzaee Javan
Fatemeh Sargolzaee Javan

5 August 2010
Verified
Journal Article
Closed access
MMMohammad Ali Mirshekar
Mohammad Ali Mirshekar
RMRoghani Mehrdad
Roghani Mehrdad
MKMohsen Khalili
Mohsen Khalili
TBTourandokht Baluchnejadmojarad
Tourandokht Baluchnejadmojarad
SMSaiedeh Arab Moazzen
Saiedeh Arab Moazzen

24 January 2020 in International Journal of Developmental Neuroscience
Verified
Journal Article
Closed access
PDF file
MBMorad Bornavard
Morad Bornavard
HFHamed Fanaei
Hamed Fanaei
MMMohammad Ali Mirshekar
Mohammad Ali Mirshekar
FMFarzaneh Farajian Mashhadi
Farzaneh Farajian Mashhadi
AAAlireza Atashpanjeh
Alireza Atashpanjeh